Video

Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.

Current Time 0:00
Duration 12:13
Loaded: 1.36%
Stream Type LIVE
Remaining Time 12:13
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    January 2023 AbbVie Inc. Company Confidential

    Related Videos
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
    Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
    Prostate cancer screening: Expert weighs in after Biden's diagnosis
    Prostate cancer screening: Expert weighs in after Biden's diagnosis
    1 expert in this video
    Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
    1 expert in this video
    Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Study results affirm effectiveness of evolving prostate cancer therapies
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    1 expert in this video
    Comparing Trials Studying Treatment Intensification In mHSPC
    An Overview of the ARANOTE Trial
    An Overview of the ARANOTE Trial
    Related Content
    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
    May 21st 2025

    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

    Hannah Clarke
    The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
    May 20th 2025

    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

    Hannah Clarke
    The phase 3 study design will now be submitted for final review by the agency.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    SBRT may offer a safe alternative to CFRT after prostatectomy
    May 16th 2025

    SBRT may offer a safe alternative to CFRT after prostatectomy

    Hannah Clarke
    Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
    Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
    May 15th 2025

    Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

    Tracey L. Krupski, MD Jeunice Owens-Walton, MD
    "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
    © 2025 MJH Life Sciences

    All rights reserved.